New Long-Acting GLP-2 Strategy Boosts Intestinal Growth in Mice
Background
Glucagon-like peptide 2 (GLP-2) is a vital gut hormone known for its role in maintaining intestinal integrity and promoting mucosal growth, making it a promising therapeutic for conditions like short bowel syndrome (SBS), Crohn's disease, and other forms of intestinal failure. However, native GLP-2 suffers from a very short circulating half-life due to rapid enzymatic degradation, which necessitates frequent, often daily, injections and limits its clinical practicality. This study addresses the critical need for a long-acting GLP-2 analog to improve therapeutic efficacy, reduce dosing frequency, and enhance patient compliance in chronic intestinal disorders.
Results
The CBB-protracted GLP-2 demonstrated significantly improved pharmacokinetics, extending the peptide's circulating half-life by approximately 5-fold compared to native GLP-2 (p<0.001), allowing for the less frequent dosing schedule. > At the 0.5 mg/kg dose, CBB-protracted GLP-2 led to a remarkable 43% increase in villus height and a 35% increase in crypt depth in the small intestine compared to the saline control group (p<0.001). This enhanced intestinal growth was 2.5-fold greater than that observed with native GLP-2 administered at the same dose (p<0.01), despite the native peptide being dosed less frequently than its typical daily regimen. Furthermore, overall mucosal thickness was increased by 38% in the high-dose CBB-GLP-2 group, indicating robust tissue regeneration. Cellular proliferation, measured by Ki-67 staining, showed a 2.8-fold increase in crypt cells (p<0.001), confirming the proliferative effect.
Why It Matters
This study presents a novel and highly effective strategy for prolonging the therapeutic action of GLP-2, significantly enhancing its potential for intestinal repair and growth through a simple formulation approach. The use of Coomassie Brilliant Blue as a non-covalent protracting agent offers an innovative and potentially cost-effective method to improve peptide pharmacokinetics without complex chemical modifications or genetic engineering. This breakthrough could pave the way for more effective, less burdensome, and potentially more accessible treatments for patients suffering from severe intestinal malabsorption and other conditions requiring enhanced gut integrity. Future research should focus on comprehensive long-term safety and immunogenicity studies of the CBB-GLP-2 complex in larger animal models, followed by toxicology assessments, before advancing to Phase I human clinical trials.